Literature DB >> 18670224

Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.

Woong Hwan Bae1, Carolyn Wester, Laura M Smeaton, Roger L Shapiro, Shahin Lockman, Kenneth Onyait, Ibou Thior, Max Essex.   

Abstract

OBJECTIVE: To assess hematologic and hepatic toxicities associated with in utero and breastfeeding exposure to maternal highly active antiretroviral therapy (HAART) among infants in Botswana.
DESIGN: A nested cohort study within a randomized clinical trial (the Mashi Study). Laboratory toxicities among infants born to women who initiated HAART before delivery were compared with toxicities among those born to women who received zidovudine and a single dose of nevirapine or placebo in labor. Infants were randomized to breastfeed with extended zidovudine or to formula-feed.
METHODS: Hemoglobin concentrations, absolute neutrophil and platelet counts, and alanine aminotransferase and aspartate aminotransferase levels were recorded from birth to 7 months of age in infants. Grade 3 and 4 toxicities were compared by infant antiretroviral exposure status.
RESULTS: In-utero exposure to maternal HAART was associated with increased risk for neutropenia in infants up to 1 month of age; 21.7% of HAART-exposed infants were neutropenic, compared with 5.5% of the infants exposed to zidovudine (P < 0.01). However, neutropenia was no longer associated with antenatal exposure to HAART after 1 month of age. Postnatal exposure to HAART was not associated with hematologic or hepatic toxicities. Laboratory toxicities were clinically asymptomatic in all but one infant.
CONCLUSION: Exposure to maternal HAART in utero may increase the risk for infant neutropenia, particularly among breastfed infants, but the clinical significance of this finding is uncertain. The lack of association between exposure to HAART through breastfeeding and long-term toxicities in infants is reassuring but deserves study in larger cohorts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18670224      PMCID: PMC2664540          DOI: 10.1097/QAD.0b013e328307a029

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  19 in total

1.  Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.

Authors:  Roger L Shapiro; Ibou Thior; Peter B Gilbert; Shahin Lockman; Carolyn Wester; Laura M Smeaton; Lisa Stevens; S Jody Heymann; Thumbi Ndung'u; Simani Gaseitsiwe; Vladimir Novitsky; Joseph Makhema; Stephen Lagakos; Max Essex
Journal:  AIDS       Date:  2006-06-12       Impact factor: 4.177

2.  Range of normal neutrophil counts in healthy zimbabwean infants: implications for monitoring antiretroviral drug toxicity.

Authors:  Jennifer Wells; Avinash K Shetty; Lynda Stranix; Meira S Falkovitz-Halpern; Tsungai Chipato; Norbert Nyoni; Patrick Mateta; Yvonne Maldonado
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-01       Impact factor: 3.731

3.  Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers.

Authors:  Madeleine J Bunders; Vincent Bekker; Henriette J Scherpbier; Kees Boer; Mieke Godfried; Taco W Kuijpers
Journal:  Acta Paediatr       Date:  2005-11       Impact factor: 2.299

4.  Age-related standards for total lymphocyte, CD4+ and CD8+ T cell counts in children born in Europe.

Authors:  Madeleine Bunders; Mario Cortina-Borja; Marie-Louise Newell
Journal:  Pediatr Infect Dis J       Date:  2005-07       Impact factor: 2.129

5.  Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment.

Authors:  Roger L Shapiro; Diane T Holland; Edmund Capparelli; Shahin Lockman; Ibou Thior; Carolyn Wester; Lisa Stevens; Trevor Peter; Max Essex; James D Connor; Mark Mirochnick
Journal:  J Infect Dis       Date:  2005-07-27       Impact factor: 5.226

6.  Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study.

Authors:  Susan E Pacheco; Kenneth McIntosh; Ming Lu; Lynne M Mofenson; Clemente Diaz; Marc Foca; Margaret Frederick; Edward Handelsman; Karen Hayani; William T Shearer
Journal:  J Infect Dis       Date:  2006-09-11       Impact factor: 5.226

7.  Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Authors:  Ellen R Cooper; Manhattan Charurat; Lynne Mofenson; I Celine Hanson; Jane Pitt; Clemente Diaz; Karen Hayani; Edward Handelsman; Vincent Smeriglio; Rodney Hoff; William Blattner
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

8.  Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.

Authors:  Ibou Thior; Shahin Lockman; Laura M Smeaton; Roger L Shapiro; Carolyn Wester; S Jody Heymann; Peter B Gilbert; Lisa Stevens; Trevor Peter; Soyeon Kim; Erik van Widenfelt; Claire Moffat; Patrick Ndase; Peter Arimi; Poloko Kebaabetswe; Patson Mazonde; Joseph Makhema; Kenneth McIntosh; Vladimir Novitsky; Tun-Hou Lee; Richard Marlink; Stephen Lagakos; Max Essex
Journal:  JAMA       Date:  2006-08-16       Impact factor: 56.272

Review 9.  Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern?

Authors:  Claire Thorne; Marie-Louise Newell
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

10.  Within and between race differences in lymphocyte, CD4+, CD8+ and neutrophil levels in HIV-uninfected children with or without HIV exposure in Europe and Uganda.

Authors:  Madeleine Bunders; Eric Lugada; Jonathan Mermin; Robert Downing; Willy Were; Claire Thorne; Marie-Louise Newell
Journal:  Ann Trop Paediatr       Date:  2006-09
View more
  20 in total

1.  Antiretroviral Treatment Is Associated With Iron Deficiency in HIV-Infected Malawian Women That Is Mitigated With Supplementation, but Is Not Associated With Infant Iron Deficiency During 24 Weeks of Exclusive Breastfeeding.

Authors:  Elizabeth M Widen; Margaret E Bentley; Charles S Chasela; Dumbani Kayira; Valerie L Flax; Athena P Kourtis; Sascha R Ellington; Zebrone Kacheche; Gerald Tegha; Denise J Jamieson; Charles M van der Horst; Lindsay H Allen; Setareh Shahab-Ferdows; Linda S Adair
Journal:  J Acquir Immune Defic Syndr       Date:  2015-07-01       Impact factor: 3.731

Review 2.  Breastfeeding and chronic HBV infection: clinical and social implications.

Authors:  Mihaela Petrova; Victor Kamburov
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

3.  Perinatal Antiretroviral Exposure and Prevented Mother-to-child HIV Infections in the Era of Antiretroviral Prophylaxis in the United States, 1994-2010.

Authors:  Kristen M Little; Allan W Taylor; Craig B Borkowf; Maria C B Mendoza; Margaret A Lampe; Paul J Weidle; Steven R Nesheim
Journal:  Pediatr Infect Dis J       Date:  2017-01       Impact factor: 2.129

4.  Increased risk of severe infant anemia after exposure to maternal HAART, Botswana.

Authors:  Scott Dryden-Peterson; Roger L Shapiro; Michael D Hughes; Kathleen Powis; Anthony Ogwu; Claire Moffat; Sikhulile Moyo; Joseph Makhema; Max Essex; Shahin Lockman
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04-15       Impact factor: 3.731

5.  Effects of concurrent exposure to antiretrovirals and cotrimoxazole prophylaxis among HIV-exposed, uninfected infants.

Authors:  Alexander C Ewing; Caroline C King; Jeffrey B Wiener; Charles S Chasela; Michael G Hudgens; Debbie Kamwendo; Gerald Tegha; Mina C Hosseinipour; Denise J Jamieson; Charles Van der Horst; Athena P Kourtis
Journal:  AIDS       Date:  2017-11-28       Impact factor: 4.177

6.  Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants.

Authors:  Jessica Fogel; Qing Li; Taha E Taha; Donald R Hoover; Newton I Kumwenda; Lynne M Mofenson; Johnstone J Kumwenda; Mary Glenn Fowler; Michael C Thigpen; Susan H Eshleman
Journal:  Clin Infect Dis       Date:  2011-04-15       Impact factor: 9.079

Review 7.  Antiretroviral medications during pregnancy for therapy or prophylaxis.

Authors:  Alice Marie Stek
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

8.  Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design.

Authors:  Paige L Williams; Rohan Hazra; Russell B Van Dyke; Cenk Yildirim; Marilyn J Crain; George R Seage; Lucy Civitello; Angela Ellis; Laurie Butler; Kenneth Rich
Journal:  AIDS       Date:  2016-01-02       Impact factor: 4.177

9.  Hematological Indices at Birth of Infants of HIV-Positive Mothers Participating in a Prevention of Mother-to-Child Transmission Program.

Authors:  Ijeoma Obumneme-Anyim; Ngozi Ibeziako; Ifeoma Emodi; Anthony Ikefuna; Tagbo Oguonu
Journal:  J Trop Pediatr       Date:  2015-09-27       Impact factor: 1.165

10.  Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk.

Authors:  Genevieve G Fouda; Frederick H Jaeger; Joshua D Amos; Carrie Ho; Erika L Kunz; Kara Anasti; Lisa W Stamper; Brooke E Liebl; Kimberly H Barbas; Tomoo Ohashi; Martin Arthur Moseley; Hua-Xin Liao; Harold P Erickson; S Munir Alam; Sallie R Permar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.